Rosuvastatin has 89 known drug interactions based on U.S. FDA drug labeling data. Of these, 11 are contraindicated combinations that should be avoided entirely. 34 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Asciminib, Cobicistat, Darunavir. Patients taking Rosuvastatin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 89
- Contraindicated
- 11
- Major
- 34
- Moderate
- 30
Contraindicated (11)
- Rosuvastatin + Asciminib— Avoid concomitant use of SCEMBLIX at all recommended doses due to increased risk of rosuvastatin adverse reactions.
- Rosuvastatin + Cobicistat— Other HMG-CoA reductase inhibitors: e.g., atorvastatin rosuvastatin ↑ HMG-CoA reductase inhibitors Coadministration of a…
- Rosuvastatin + Darunavir— Lipid Modifying Agents: HMG-CoA reductase inhibitors: lovastatin, simvastatin atorvastatin, pravastatin, rosuvastatin Ot…
- Rosuvastatin + Darunavir 600 Mg— Lipid Modifying Agents: HMG-CoA reductase inhibitors : lovastatin, simvastatin atorvastatin, pravastatin, rosuvastatin O…
- Rosuvastatin + Darunavir Ethanolate And Cobicistat— atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin ↑ atorvastatin ↑ fluvastatin ↑ pravastatin ↑ rosuvast…
- Rosuvastatin + Darunavir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide— e.g., atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin ↑ atorvastatin ↑ fluvastatin ↑ pravastatin ↑ ro…
- Rosuvastatin + Ledipasvir And Sofosbuvir— Combination may significantly increase rosuvastatin exposure. Concomitant use with rosuvastatin is not recommended.
- Rosuvastatin + Lopinavir And Ritonavir— Lipid-modifying agents HMG-CoA Reductase Inhibitors: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyc…
- Rosuvastatin + Ritonavir— Lipid-modifying agents HMG-CoA Reductase Inhibitor: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyce…
- Rosuvastatin + Ritonavir 100 Mg— Lipid-modifying agents HMG-CoA Reductase Inhibitor: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyce…
- Rosuvastatin + Sofosbuvir, Velpatasvir, And Voxilaprevir— Combination increases rosuvastatin exposure. Use with rosuvastatin tablets is not recommended.
Major (34)
- Rosuvastatin + Atazanavir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
- Rosuvastatin + Capmatinib— Capmatinib increased rosuvastatin exposure more than 2.1-fold, increasing the risk of myopathy and rhabdomyolysis. Do no…
- Rosuvastatin + Colchicine— Cases of myopathy, including rhabdomyolysis, have been reported with rosuvastatin coadministered with colchicine. Cautio…
- Rosuvastatin + Cyclosporine— Cyclosporine increased rosuvastatin exposure 7-fold, significantly increasing the risk of myopathy and rhabdomyolysis. D…
- Rosuvastatin + Danicopan— Danicopan significantly increased rosuvastatin exposure. Dose should not exceed 10 mg once daily when used concomitantly…
- Rosuvastatin + Darolutamide— Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily.
- Rosuvastatin + Dasabuvir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
- Rosuvastatin + Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir— Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.
- Rosuvastatin + Elbasvir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
- Rosuvastatin + Elbasvir And Grazoprevir— Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.
- Rosuvastatin + Eltrombopag— OATP1B1 and BCRP substrate; eltrombopag increases exposure. 50% dose reduction was recommended in clinical trials.
- Rosuvastatin + Enasidenib— Enasidenib increased rosuvastatin exposure more than 2.4-fold, increasing the risk of myopathy and rhabdomyolysis. Do no…
- Rosuvastatin + Febuxostat— Febuxostat increased rosuvastatin exposure more than 1.9-fold, increasing the risk of myopathy and rhabdomyolysis. Do no…
- Rosuvastatin + Fostamatinib— Fostamatinib increased rosuvastatin exposure more than 2.0-fold, increasing the risk of myopathy and rhabdomyolysis. Do …
- Rosuvastatin + Gemfibrozil— Avoid concomitant use of gemfibrozil with rosuvastatin. If concomitant use cannot be avoided, initiate rosuvastatin at 5…
- Rosuvastatin + Glecaprevir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
- Rosuvastatin + Glecaprevir And Pibrentasvir— Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.
- Rosuvastatin + Grazoprevir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
- Rosuvastatin + Ledipasvir— Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin.
- Rosuvastatin + Lopinavir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
- Rosuvastatin + Ombitasvir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
- Rosuvastatin + Oral Anticoagulants— Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin and monitor frequently upon initiation or al…
- Rosuvastatin + Paritaprevir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
- Rosuvastatin + Pibrentasvir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
- Rosuvastatin + Regorafenib— Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.
- Rosuvastatin + Resmetirom— REZDIFFRA increases plasma concentrations of rosuvastatin; limit daily dosage to 20 mg to reduce risk of statin-related …
- Rosuvastatin + Simeprevir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
- Rosuvastatin + Sofosbuvir— Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin. Simepre…
- Rosuvastatin + Teriflunomide— Teriflunomide increased rosuvastatin exposure more than 2.5-fold, increasing the risk of myopathy and rhabdomyolysis. Do…
- Rosuvastatin + Tipranavir— HMG-CoA Reductase Inhibitors: Atorvastatin Rosuvastatin ↑ Atorvastatin ↓ Hydroxy-atorvastatin metabolites ↑ Rosuvastatin…
- Rosuvastatin + Velpatasvir— Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin. Simepre…
- Rosuvastatin + Velpatasvir And Sofosbuvir— Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.
- Rosuvastatin + Voclosporin— OATP1B1/OATP1B3 substrate; voclosporin increases exposure. Monitor for myopathy and rhabdomyolysis; reduce dosage as rec…
- Rosuvastatin + Voxilaprevir— Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin.
Moderate (30)
- Rosuvastatin + Aluminum & Magnesium Hydroxides— Antacids may reduce rosuvastatin absorption. Administer rosuvastatin at least 2 hours before the antacid.
- Rosuvastatin + Desogestrel And Ethinyl Estradiol And Ethinyl Estradiol— Co-administration increases AUC of ethinyl estradiol by approximately 20-25%.
- Rosuvastatin + Elagolix— Statins: rosuvastatin ↓ rosuvastatin Monitor lipid levels and adjust the dose of rosuvastatin, if necessary.
- Rosuvastatin + Elagolix And Estradiol And Norethisterone— Statins: rosuvastatin ↓ rosuvastatin Monitor lipid levels and adjust the dose of rosuvastatin, if necessary.
- Rosuvastatin + Eltrombopag Olamine— 7.2 Transporters Use caution when concomitantly administering PROMACTA and drugs that are substrates of OATP1B1 (e.g., a…
- Rosuvastatin + Eluxadoline— Increased exposure to rosuvastatin when co-administered with VIBERZI with a potential for increased risk of myopathy/rha…
- Rosuvastatin + Fenofibrate— No clinically significant increase in AUC observed, but risk of myopathy is increased with concomitant use of fenofibrat…
- Rosuvastatin + Fibrates— Use with fibrates increases risk of adverse skeletal muscle effects. Caution should be used when prescribing with rosuva…
- Rosuvastatin + Fosamprenavir— Fosamprenavir/ritonavir produces little or no change in rosuvastatin exposure. Caution should be exercised when coadmini…
- Rosuvastatin + Fostemsavir Tromethamine— Statins: Rosuvastatin b Atorvastatin Fluvastatin Pitavastatin Simvastatin ↑Rosuvastatin ↑Atorvastatin ↑Fluvastatin ↑Pita…
- Rosuvastatin + Leflunomide— Teriflunomide may increase exposure of rosuvastatin. Dose should not exceed 10 mg once daily.
- Rosuvastatin + Lenacapavir Sodium— Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use with caution when midazolam or triazo…
- Rosuvastatin + Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol Tablets— Rosuvastatin increases AUC of ethinyl estradiol by approximately 20 to 25% when co-administered with certain COCs.
- Rosuvastatin + Levonorgestrel And Ethinyl Estradiol And Ferrous Fumarate— Increases AUC values for ethinyl estradiol by approximately 20-25%.
- Rosuvastatin + Levonorgestrel/Ethinyl Estradiol And Ethinyl Estradiol— Increases systemic exposure of ethinyl estradiol by approximately 20-25 percent.
- Rosuvastatin + Momelotinib— Momelotinib is a BCRP inhibitor that may increase rosuvastatin exposure. Initiate rosuvastatin at 5 mg and do not increa…
- Rosuvastatin + Niacin— Lipid-modifying doses (≥1 g/day) of niacin increase risk of adverse skeletal muscle effects with rosuvastatin. Caution s…
- Rosuvastatin + Norelgestromin And Ethinyl Estradiol— Co-administration increases AUC values for ethinyl estradiol by approximately 20-25%.
- Rosuvastatin + Norethindrone Acetate, Ethinyl Estradiol And Ferrous Fumarate— Co-administration increases AUC values for ethinyl estradiol by approximately 20-25%.
- Rosuvastatin + Norethindrone Acetate/Ethinyl Estradiol— Increases AUC values for ethinyl estradiol by approximately 20 to 25%.
- Rosuvastatin + Norethindrone And Ethinyl Estradiol— May increase ethinyl estradiol AUC by approximately 20-25% when co-administered.
- Rosuvastatin + Norgestimate And Ethinyl Estradiol— Co-administration increases AUC of ethinyl estradiol by approximately 20-25%, potentially increasing hormone exposure.
- Rosuvastatin + Norgestrel And Ethinyl Estradiol— Increases AUC of ethinyl estradiol by approximately 20-25%.
- Rosuvastatin + Oteseconazole— Oteseconazole inhibits BCRP, increasing exposure of rosuvastatin. Monitor for adverse reactions and consider dose reduct…
- Rosuvastatin + Rosuvastatin Calcium— 7 DRUG INTERACTIONS See full prescribing information for details regarding concomitant use of rosuvastatin tablets with …
- Rosuvastatin + Segesterone Acetate And Ethinyl Estradiol— Co-administration increases systemic exposure of ethinyl estradiol by approximately 20-25%.
- Rosuvastatin + Tafamidis Meglumine— Tafamidis inhibits BCRP, increasing rosuvastatin exposure and toxicity risk. Monitor for toxicities and adjust dosage if…
- Rosuvastatin + Tedizolid Phosphate— If coadministration cannot be avoided, monitor for adverse reactions related to the concomitantly administered BCRP subs…
- Rosuvastatin + Ticagrelor— (7.4) Rosuvastatin plasma concentrations may increase. 7.4 Simvastatin, Lovastatin, Rosuvastatin Ticagrelor increases se…
- Rosuvastatin + Warfarin— Rosuvastatin may increase warfarin effects. Monitor INR frequently upon initiation, dose titration, or discontinuation o…